MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.

[1]  S. Sleijfer,et al.  MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer , 2011, Breast Cancer Research and Treatment.

[2]  B. Nielsen,et al.  Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. , 2010, Methods.

[3]  Brigitte Rack,et al.  Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer , 2010, Breast Cancer Research.

[4]  David Galas,et al.  Complexity of the microRNA repertoire revealed by next-generation sequencing. , 2010, RNA.

[5]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[6]  Takahiro Ochiya,et al.  Secretory microRNAs as a versatile communication tool , 2010, Communicative & integrative biology.

[7]  M. Korc,et al.  Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors , 2010, Clinical Cancer Research.

[8]  Michael J Kerin,et al.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. , 2010, The oncologist.

[9]  R. Weinberg,et al.  Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. , 2010, Cancer research.

[10]  Wei Xiong,et al.  MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* , 2010, The Journal of Biological Chemistry.

[11]  A. Mercurio,et al.  miR-10b Targets Tiam1 , 2010, The Journal of Biological Chemistry.

[12]  Shuai Jiang,et al.  MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. , 2010, Cancer research.

[13]  J. Baselga,et al.  HER2 signatures in breast cancer: ready to go to print? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Domenico Coppola,et al.  MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer* , 2010, The Journal of Biological Chemistry.

[15]  Y. Matsuki,et al.  Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells*♦ , 2010, The Journal of Biological Chemistry.

[16]  Li Xie,et al.  MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression , 2010, Journal of experimental & clinical cancer research : CR.

[17]  A. Lal,et al.  MicroRNAs and their target gene networks in breast cancer , 2010, Breast Cancer Research.

[18]  Hyunsuk Shim,et al.  Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. , 2010, Biochemical pharmacology.

[19]  Michael J Kerin,et al.  Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer , 2010, Annals of surgery.

[20]  Robert A. Weinberg,et al.  Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model , 2010, Nature Biotechnology.

[21]  G. Mills,et al.  miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells , 2010, Cell Death and Differentiation.

[22]  Y. Mo,et al.  MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. , 2010, Cancer research.

[23]  Thomas Streichert,et al.  Identification of differentially expressed microRNAs in human male breast cancer , 2010, BMC Cancer.

[24]  Israel Steinfeld,et al.  Novel Rank-Based Statistical Methods Reveal MicroRNAs with Differential Expression in Multiple Cancer Types , 2009, PloS one.

[25]  Stefano Volinia,et al.  MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets , 2009, The Journal of pathology.

[26]  K. Moelling,et al.  A Short Hairpin DNA Analogous to miR-125b Inhibits C-Raf Expression, Proliferation, and Survival of Breast Cancer Cells , 2009, Molecular Cancer Research.

[27]  Xudong Dai,et al.  MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT , 2009, Cell cycle.

[28]  Hong Chen,et al.  Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559. , 2009, Biochemical and biophysical research communications.

[29]  S. D. Selcuklu,et al.  miR-21 as a key regulator of oncogenic processes. , 2009, Biochemical Society transactions.

[30]  A. Barker,et al.  miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer* , 2009, The Journal of Biological Chemistry.

[31]  L. Sidéris,et al.  Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer , 2009, Current oncology.

[32]  R. Weinberg,et al.  A Pleiotropically Acting Microrna, Mir-31, Inhibits Breast Cancer Metastasis Accessed Terms of Use Detailed Terms a Pleiotropically Acting Microrna, Mir-31, Inhibits Breast Cancer Metastasis , 2022 .

[33]  I. Faraoni,et al.  miR-155 gene: a typical multifunctional microRNA. , 2009, Biochimica et biophysica acta.

[34]  Wei Shi,et al.  Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues , 2009, Laboratory Investigation.

[35]  Ulus Atasoy,et al.  Circulating microRNAs in breast cancer and healthy subjects , 2009, BMC Research Notes.

[36]  Michael T. McManus,et al.  Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion* , 2009, The Journal of Biological Chemistry.

[37]  Jing Li,et al.  miR-145 inhibits breast cancer cell growth through RTKN. , 2009, International journal of oncology.

[38]  C. Klinge,et al.  Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells , 2009, Nucleic acids research.

[39]  F. Cardoso,et al.  Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. , 2009, Current cancer drug targets.

[40]  W. Han,et al.  The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. , 2009, American journal of surgery.

[41]  C. Lee,et al.  MicroRNA and cancer – focus on apoptosis , 2008, Journal of cellular and molecular medicine.

[42]  Hailong Wu,et al.  Suppression of cell growth and invasion by miR-205 in breast cancer , 2008, Cell Research.

[43]  B. Qian,et al.  High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1 , 2009, Breast Cancer Research and Treatment.

[44]  Stefano Volinia,et al.  MicroRNA expression profiling of male breast cancer , 2009, Breast Cancer Research.

[45]  H. Hollema,et al.  Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma , 2009, BMC Cancer.

[46]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[47]  A. Rashid,et al.  MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers , 2008, Oncogene.

[48]  Xiao-Hua Zhang,et al.  [Expression of microRNA-21 in invasive ductal carcinoma of the breast and its association with phosphatase and tensin homolog deleted from chromosome expression and clinicopathologic features]. , 2008, Zhonghua yi xue za zhi.

[49]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[50]  Malachi Griffith,et al.  In-depth characterization of the microRNA transcriptome in a leukemia progression model. , 2008, Genome research.

[51]  Domenico Coppola,et al.  MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA , 2008, Molecular and Cellular Biology.

[52]  John W M Martens,et al.  Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.

[53]  Xiuping Liu,et al.  Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. , 2008, Biochemical pharmacology.

[54]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[55]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[56]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[57]  Carme Camps,et al.  hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer , 2008, Clinical Cancer Research.

[58]  R. Place,et al.  MicroRNA-373 induces expression of genes with complementary promoter sequences , 2008, Proceedings of the National Academy of Sciences.

[59]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[60]  Asli Silahtaroglu,et al.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.

[61]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.

[62]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[63]  G. Viani,et al.  Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials , 2007, BMC Cancer.

[64]  G. Lutz,et al.  Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice , 2008, BMC biotechnology.

[65]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  J. Fridlyand,et al.  Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. , 2007, Cancer research.

[67]  C. Benz,et al.  Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b* , 2007, Journal of Biological Chemistry.

[68]  Peter A Kaufman,et al.  HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[70]  A. Dueñas-González,et al.  Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. , 2006, Cancer treatment reviews.

[71]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[73]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[74]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[75]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[76]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[77]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[78]  B. Cullen,et al.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[79]  P. Goss,et al.  Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.

[80]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[81]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[82]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.